Cargando…

Microbiota-associated immunotherapy resistance caused by deficient PD-L2 - RGMb signaling

In a recent paper in Nature, Park et al. propose a mechanism through which intestinal dysbiosis compromises the efficacy of immunotherapy targeting the PD-L1/PD−1 interaction. Dysbiosis may upregulate a pair of checkpoint molecules, i.e. PD-L2 interacting with RGMb. Antibodies targeting PD-L2/RGMb c...

Descripción completa

Detalles Bibliográficos
Autores principales: Fidelle, Marine, Lebhar, Isabelle, Zitvogel, Laurence, Kroemer, Guido
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10308862/
https://www.ncbi.nlm.nih.gov/pubmed/37396957
http://dx.doi.org/10.1080/2162402X.2023.2224679
Descripción
Sumario:In a recent paper in Nature, Park et al. propose a mechanism through which intestinal dysbiosis compromises the efficacy of immunotherapy targeting the PD-L1/PD−1 interaction. Dysbiosis may upregulate a pair of checkpoint molecules, i.e. PD-L2 interacting with RGMb. Antibodies targeting PD-L2/RGMb can restore responses to PD−1 blockade in the context of dysbiosis.